General MedicationsORALStandard
KYGEVVI
DOXECITINE; DOXRIBTIMINE
Standard Dose
2GM/PACKET;2GM/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview KYGEVVI is listed in Drugs@FDA under application 219792 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient DOXECITINE; DOXRIBTIMINE Form and strength FOR SOLUTION;ORAL - 2GM/PACKET;2GM/PACKET Sponsor UCB INC Submission history Latest submission status date: 2025-11-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview KYGEVVI is listed in Drugs@FDA under application 219792 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient DOXECITINE; DOXRIBTIMINE Form and strength FOR SOLUTION;ORAL - 2GM/PACKET;2GM/PACKET Sponsor UCB INC Submission history Latest submission status date: 2025-11-03 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.